Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for antibiotic-resistant infections. Its main product is AP-SA01 that targets Staphylococcus aureus including multidrug-resistant strains. The company also develops a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals was formed as a result of the merger between C3J Therapeutics and AmpliPhi Biosciences.